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TREATMENT OF TRICHOMONIASIS IN
WOMEN WITH CHRONIC INFLAMMATORY
DISEASES OF FEMALE GENITAL ORGANS
Abstract. A clinical and laboratory examination of 50 women with
chronic inflammatory diseases of female genitals having Trichomonas,
who were divided into 2 groups: I group - 25 women who were
administered short schemes of trichomoniasis treatment with large
doses of metronidazole, II group - 25 women who undergone the
treatment with average therapeutic dose for 7-10 days was carried
out. Treatment was reliably more effective at treating trichomoniasis
for 7-10 days..
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Introduction
In recent years there has been an increased
incidence of urogenital infections that differ
polietiolohichnistiu, atypical clinical symptoms, the
formation of chronic diseases and the spread of these
diseases in the population that requires a differen-
tiated approach to treatment [1]. The spectrum of
causative agents of urogenital infections is extremely
high - from specific pathogens TORCH-complex to
pathogenic flora [3]. Increasingly important in the
formation of chronic urogenital infections become
such groups of microorganisms - conditionally
pathogenic microflora and protozoa, especially
Trichomonas [1,4]. According to WHO, tricho-
moniasis infection is ditected in almost 10% of the
population [2]. In certain socio-economic groups, the
prevalence of trichomoniasis may reach 40-90% [1].
In the female genital Trichomoniasis can coexist with
gonococcus, herpes simplex virus, Chlamydia,
Corynebacterium and other microorganisms that are
found in the lower genital area. Absorbing pathogens
Trichomonas are agents of infectious pathogens in
the upper sections of organs and abdominal cavity
[1]. The importance of the problem is caused not
only with widespread disease, but the consequences
that arise as a result of the action of microorganisms
and the emergence of complications that can cause
infertility, pathology of pregnancy and childbirth.
Chronic persistence of pathogens in the female
reproductive organs affects the body as a whole and
also causes changes in the immune system with the
development of secondary immunodeficiency. [3]
The purpose of the study
To investigate the state of mikrobiotsynozu of the
vagina in women with chronic inflammatory diseases
of the female genital organs, including the presence
of Trichomonas vaginalis and to determine effective
treatment in the application of different treatment
regimens of trichomoniasis.
Materials and methods
To achieve this goal we conducted clinical and
laboratory examination of 86 women with chronic
inflammatory diseases of the female genital organs,
50 of whom were allocated Trichomonas (58.12%)
and 20 gynecological healthy women who created
the control group.
All women were somatically healthy, in anam-
nesis they had inflammatory diseases of female
genital mutilation. Age of women ranged from 22 to
39 years (mean 30,5 ± 0,45 years).
The material for the study were the allocation of
the vagina and cervix, scraping columnar epithelium
of the cervical canal.
Methods - Bacterioscopic, bacteriological, statistical.
Option study - a longitudinal study.
Discussion of the results of the study
The study established the presence of trichomo-
niasis in 58.12% of women with chronic inflam-
matory diseases of the female genital organs.
A characteristic feature of Trichomonas infection of
the mucous membrane of the vagina and cervix in 50
women was the presence of polymicrobial asso-
ciation with opportunistic pathogens in 36 cases
(72%) of pathogenic - in 14 cases (18%). Tricho-
monas coexisted with yeast fungi genus Candida,
staphylococcus - golden and epidermal, Escherichia,
Chlamydia, ureaplasma, mycoplasma, herpes
simplex virus (opportunistic), and gonococcus and
fecal enterococci (pathogens). The 20 women of the
control group revealed Candida albicans - 2 cases -
10%, fecal enterococcus - 1 case - 5%, lactobacilli,
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Corynebacterium - 17 cases - 85%. Trichomonas create
associations with such opportunistic pathogens:
Candida albicans - 12 cases - 24%, S.epidermidis - 7
cases - 14%, E. coli - 9 cases - 18%, S.epidermidis and
E. coli - 6 cases - 12%, chlamydia - 8 cases - 16%,
herpes simplex virus - 4 cases - 8%, chlamydia, and
viruses Herpes Simplex - 3 cases - 6%. In the remaining
36 (41.86%) women of the main group such
microorganisms as S.epidermidis, E. coli - 15 cases -
41.67%, Candida albicans - 5 cases - 13.89%,
Chlamydia - 5 cases - 13.89%, fecal enterococcus - 2
cases - 5.56%, chlamydia, ureaplasma, mycoplasma - 6
cases - 16.67%, herpes simplex virus - 2 cases - 5.56%,
herpes simplex virus, chlamydia, S.epidermidis - 4
cases - 11.11% have been revealed.
Women with trichomoniasis diagnosis were
divided into 2 groups: I group - 25 women who iwere
prescribed short treatment regimen with large doses
of metronidazole (2.0 per day per os and 1.0 topically
as vaginal suppositories), II group - 25 women who
mere prescribed the treatment with medium doses
(1.0 per day per os and 0.5 topically as vaginal
suppositories) for 7-10 days.
After examination of women after the first course
of treatment, the presence of trichomonads has been
stated in 22 women of the first group and 23 women
of the 2nd one.
Treatment during one menstrual cycle was
ineffective. Significant differences were detected. All
women continued treatment for three menstrual
cycles. The effectiveness of the treatment was judged
by clinical symptoms and absence of Trichomonas
vaginalis in smears during examination in month
after the treatment. Treatment was effective in 9
women of the first group (40.9% ± 12,6) and 18
women (78.3%±9,4) (p <0,05) of the second group.
After receiving the results of the study we have
made a conclusion as to significant differences in the
treatment of trichomoniasis using different regimens.
Treatment with metronidazole for 7-10 days at a dose
of 1.5 was significantly more effective than an
increased single dose of the drug.
Conclusions
1. Trichomonas, associating with other opportunistic
pathogens and pathogenic microorganisms contribute to
the development of chronic inflammatory diseases of
female genital mutilation.
2. Insufficient effectiveness of trichomoniasis
treatment of only during one menstrual cycle,
regardless metronidazole dose and duration of
treatment (p> 0.5) has been established.
3. We found a significant difference when
applying medium therapeutic doses of metronidazole
for 7-10 days and a single dose of 3.0 metronidazole
for three menstrual cycles.
Prospects for further research
Determination of the effectiveness of treatment in
the application of different schemes, depending on
the duration of the disease
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æ³íîê ³ç õðîí³÷íèìè çàïàëüíèìè çàõâîðþâàííÿìè æ³íî÷èõ
ñòàòåâèõ îðãàí³â çà íàÿâíîñò³ òðèõîìîíàä, ÿê³ áóëè ðîçä³ëåí³
íà 2 ãðóïè: ² ãðóïà – 25 æ³íîê, ÿêèì ïðèçíà÷àëèñÿ êîðîòê³
ñõåìè ë³êóâàííÿ òðèõîìîí³àçó âåëèêèìè äîçàìè ìåòðîí³äà-
çîëó, ²² ãðóïà – 25 æ³íîê, ÿêèì ïðîâîäèëîñÿ ë³êóâàííÿ ñåðåä-
íüîþ òåðàïåâòè÷íîþ äîçîþ âïðîäîâæ 7-10 äí³â. Ë³êóâàííÿ
áóëî äîñòîâ³ðíî åôåêòèâí³øèì ïðè 7-10 äåííîìó ë³êóâàíí³
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Ðåçþìå. Ïðîâåäåíî êëèíèêî-ëàáîðàòîðíîå îáñëåäîâàíèå
50 æåíùèí ñ õðîíè÷åñêèìè âîñïàëèòåëüíûìè çàáîëå-
âàíèÿìè æåíñêèõ ïîëîâûõ îðãàíîâ ïðè íàëè÷èè òðèõî-
ìîíàä, êîòîðûå áûëè ðàñïðåäåëåíû íà 2 ãðóïû: ² ãðóïà – 25
æåíùèí, êîòîðûì íàçíà÷ààëèñü êðàòêèå ñõåìû ëå÷åíèÿ
òðèõîìîíèàçà áîëüøèìè äîçàìè ìåòðîíèäàçîëà, ²² ãðóïà –
25 æåíùèí, êîòîðûì ïðîâîäèëîñü ëå÷åíèÿ ñðåäíåé òåðà-
ïåâòè÷åñêîé äîçîé äëèòåëüíîñòüþ 7-10 äíåé. Ëå÷åíèå áóëî
äîñòîâåðíî ýôåêòèâíåå ïðè 7-10 äíåâíîì ëå÷åíèè
òðèõîìîíèàçà.
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